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Figure: Anglographic views
Top= complete occlusion of left anterior descending coronary artery
(arrow); middle= after ultrasound application; bottom= after
additional balloon angioplasty.
introduced into coronary arteries.6 We describe a patient with
acute myocardial infarction treated with ultrasound.
A 48-year-old woman presented 4 h after the onset of chest
pain with ST elevation in all anterior leads. Because of
Wolf-Parkinson-White syndrome and atypical chest pain she
was immediately referred to the catheterisation laboratory.
Coronary angiography showed a thrombotic occlusion of the
proximal left anterior descending artery (figure, top). After
informed consent was obtained, the lesion was easily crossed
with a 0-36 mm guide wire. Over the guide wire the ultrasonic
probe was advanced through an 8 French guiding catheter to
the lesion. The tip of the probe (1 -7 mm diameter) crossed after
5 min of ultrasound application. Angiographically the lesion
appeared smooth with a residual diameter stenosis of 64%
(figure, middle).
The patient was maintained on high-dose heparin (partial
thromboplastin time > 180 s) and developed a creatine kinase
peak of 1254 U/L 6 h after recanalisation. The next day the
patient was restudied by intravascular ultrasound imaging
(Hewlett Packard, Boston Scientific), which showed a soft
plaque with a minimum lumen diameter of 1-6 mm. Balloon
angiplasty at 3-04 x 105 Pa with a 2 5 mm balloon improved the
lumen angiographically to a 40% diameter stenosis (figure,
bottom). By ultrasound imaging the minimum diameter was
2-3 mm without dissection. Further clinical follow-up was
uneventful up to discharge after 10 days. A right posterior
accessory atrioventricular pathway was successfully treated by
radiofrequency ablation 6 days after angioplasty.
This case shows that ultrasound angioplasty may be a
potential alternative to balloon angioplasty and thrombolysis in
patients with acute thrombotic coronary occlusions. Further
experience is needed to establish safety and to define the role of
this new technique in fresh thrombotic occlusions.
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Bipolar affective psychosis after vigabatrin
SiR-Vigabatrin is a new and effective inhibitor of gamma-
aminobutyric acid (GABA) transaminase used in the treatment
of therapy-resistant epilepsy. Depression has been reportedl in
about 4% of patients on vigabatrin and also postictal or
alternative psychoses3 with schizophrenia-like symptoms after
effective reduction of seizure frequency. We report a patient
with bipolar affective psychosis after vigabatrin.
A 51-year-old male patient had drug-resistant temporal lobe
epilepsy for 26 years due -to a benign left-hemispherical
temporomesial lesion. Neither he nor his family had a history of
affective disorders. Antiepileptic treatment with monotherapy
of carbamazepine, phenytoin, or barbiturates in high doses
failed to control seizure activity, but combined medication with
carbamazepine (2-8 g daily) and phenytoin (0-5 g daily)
achieved a reduction of fits to two temporal lobe attacks per
month. However, major sedative side-effects were found to be
intolerable and phenytoin was substituted by vigabatrin (3 g
daily). This treatment was well tolerated, the attacks fell to less
than one a month, and there was no longer any sedation.
However, 10 weeks after vigabatrin had been added the patient
had a hypomanic episode that subsided spontaneously within 4
weeks. 2 months later he developed severe depression and
attempted suicide by cutting his wrists. He exhibited
delusional thinking with ideas of worthlessness and
inappropriate guilt. He also had somatic delusions and was
convinced that he had cancer. On admission he was depressed
and a few days later he developed a rapid-cycling type of
affective psychosis with depressed mood in the morning and a
manic state in the afternoon and evening. The manic state was
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characterised by flight of ideas, hyperactivity, socially intrusive
behaviour, and lack of concentration. He also showed
symptoms of derealisation. An electroencephalogram (EEG)
showed a 6-7 Hz theta rhythm with intermittent frontal
bilateral delta waves. No spikes or sharp waves were detected.
Before vigabatrin the EEG had shown a slow 8 Hz alpha
rhythm with single bilateral theta-waves without epileptic
activity.
After slow withdrawal of vigabatrin and addition of
thioridazine 360 mg daily his mood stabilised progressively.
Depression subsided within 2 weeks of admission, although he
remained hyperactive in the afternoon. Hyperactivity and
decreased concentration normalised within the following 8
weeks, corresponding well to psychological test results and
improvement of EEG recordings to a slow alpha rhythm, as
documented before vigabatrin treatment. Although his mood
remained stable, some behavioural alterations persisted
including circmstantiality and interpersonal viscosity, as
frequently observed in patients with temporal lobe epilepsy.4
The bipolar affective psychosis reported here after
vigabatrin confirms and extends previous findings related to
GABAergic neurotransmission in the development of mood
disorders. However, the effect of GABA alone on mood is
controversial,2.5,6 Our observation suggests that alterations of
the GABAergic system not only induce depression, but also
may trigger bipolar affective disorders with rapid cycling.
Patients with an affective psychosis in their previous history
might have a higher risk.’ Whether this is also true when there
is a pre-existing cerebral lesion as found in our patient is not
known. Depressive and manic states must be recognised early
in the treatment of epilepsies to avoid serious complications
such as suicide. Further studies are needed to identify patients
who are susceptible to the psychotomimetic action of the drug,
but in view of the seriousness of its side-effects, we recommend
that vigabatrin should be confined to patients with otherwise
intractable seizures.
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Serotonin syndrome
SIR-Neuvonen and colleagues (Dec 4, p 1419) indicate that
death may occur due to interactions with moclobemide. The
older monoamine oxidase inhibitors (MAOIs) are well known
to cause the "cheese" reaction, a hypertensive crisis brought
about by interaction with certain foods and drugs, but this is
unlikely to occur with moclobemide.1 The clinical syndrome
that results from interactions between MAOIs and drugs such
as clomipramine and citalopram, and also from acute overdose,
is less well known. It consists of a serotonin syndrome with a
progressive increase in muscle tone leading to widespread
muscle spasms, trismus, opisthotonus, and hyperthermia with
profuse sweating, tachycardia, hypotension, and widely dilated
Tt-ctt
Figure: Yearly fatal toxicity Indices (deaths per million
prescriptions, England and Wales) for three major
antidepressant drug groups, 1987-91
pupils;2,3 death is likely to result from hyperthermia,
cardiovascular collapse, or disseminated intravascular
coagulation. The London National Poisons Information
Service has for several years provided management guidance
that MAOI overdose or interaction patients with a core
temperature of over 390C should be electively paralysed and
mechanically ventilated.4 Our experience is that patients who
are paralysed before serious complications have developed
generally survive. We also believe that this policy has been
effective since there has been a steady reduction in the fatal
toxicity index of MAOIs each year for the past few years
(figure).
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Pancreas transplantation
SiR-Remuzzi and colleagues (Jan 1, p 27) claim that a
prospective randomised comparison is needed before
conclusions can be drawn about the effects of pancreas
transplantation. Such trials are difficult because few operations
are done in any one centre and multicentre studies are biased by
the "centre effect" (immunosuppressive schedules differ
greatly between centres). Moreover, the clinical status of
uraemic diabetic patients undergoing pancreas transplantation
will be so heterogeneous that effective randomisation is
unrealistic.
Simultaneous kidney/pancreas transplantation failure rates
are, in experienced hands, close to those achieved with kidney
or with heart transplantation. 1-year-survival rates (and
pancreas rejection rates) are 97% (13%) in Omaha, 90% (14%)
in Madison, 93 % (16%) in Milan, and 95 % (27%) in Nantes.
Moreover, the data reported by Remuzzi refer to 1992 registry
results: further improvement was recorded by the international
registry in 1993.
Among side-effects of immunosuppressive therapy
